Curcumin and Curcuma longa Extract in the Treatment of 10 Types of Autoimmune Diseases: A Systematic Review and Meta-Analysis of 31 Randomized Controlled Trials.

The short version

This systematic review and meta-analysis pooled 31 randomized controlled trials (34 study records, roughly 1,583 participants) exploring curcumin and Curcuma longa (turmeric) extract across 10 autoimmune diseases — conditions where the immune system mistakenly attacks the body's own tissue. Autoimmune disease covers more than 120 named conditions; this review focused on ankylosing spondylitis, Behçet's disease, Crohn's disease, multiple sclerosis, oral lichen planus, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, Takayasu arteritis, and ulcerative colitis. Curcumin is the main active compound in turmeric, long used in Chinese medicine, and is studied here for its ability to regulate immune cells and reduce inflammation. Researchers searched English and Chinese databases plus the Cochrane Library and ClinicalTrials.gov through February 2022, screening 2,991 records down to 31 RCTs that tested curcumin or Curcuma longa extract against placebo or usual care. Trial count per disease varied widely: 9 RCTs for ulcerative colitis and 6 for oral lichen planus, but only 1 each for ankylosing spondylitis, Behçet's disease, and Takayasu arteritis. Doses ranged from 60 mg to 6,000 mg daily, taken orally, or in some trials applied as a gel, mouthwash, or enema, for 2 to 96 weeks. Disease activity was tracked with condition-specific scales (PASI for psoriasis, DAS28 for rheumatoid arthritis, EDSS for multiple sclerosis, and others) alongside blood markers like ESR and CRP. Where enough trials existed to combine statistically, curcumin performed well. In psoriasis, it roughly tripled the rate of major skin-clearance (PASI75: RR=3.01, p=0.008—meaning patients getting curcumin were about three times as likely to see substantial improvement). In ulcerative colitis, it raised clinical remission more than twofold (RR=2.28, p=0.0005) and lowered inflammatory markers ESR and CRP. In rheumatoid arthritis, it reduced the DAS28 disease-activity score (WMD=-1.10, p=0.0002—a clinically noticeable drop in joint disease activity), though results varied considerably between the five trials. Oral lichen planus, despite being studied in six trials, did not show a significant benefit on its pooled lesion-severity score (p=0.17). None of the pooled analyses found more side effects with curcumin than with placebo. The other six diseases each had just one or two small trials reporting improvement, too few to combine or confirm. These findings support curcumin as a reasonably safe adjunct for psoriasis, ulcerative colitis, and rheumatoid arthritis specifically, where the evidence is strongest and most consistent; for the seven other diseases, results are preliminary and should not yet guide treatment decisions. Curcumin's poor absorption from the gut remains a practical obstacle to reliable dosing. The authors call for larger, multi-center trials, especially for the thinly studied conditions, before broader clinical recommendations can be made.

Key findings

• A meta-analysis of 31 randomized controlled trials (RCTs) — studies where patients are randomly assigned to a treatment or comparison group — found that curcumin, the active compound in turmeric (Curcuma longa), significantly improved psoriasis skin severity, ulcerative colitis remission rates, and rheumatoid arthritis disease activity compared with placebo or standard care.
• Curcumin doses in the reviewed trials ranged from 60 mg to 6,000 mg per day, taken for as little as 2 weeks or as long as 96 weeks (nearly two years), most often as an oral capsule but sometimes as a topical gel, mouthwash, or enema depending on the condition treated.
• None of the trials that measured side effects found curcumin caused more adverse events than placebo, and the U.S. Food and Drug Administration (FDA) classifies curcumin as Generally Recognized As Safe (GRAS).
• For seven other autoimmune diseases studied — ankylosing spondylitis, Behçet's disease, Crohn's disease, multiple sclerosis, oral lichen planus, systemic lupus erythematosus (SLE), and Takayasu arteritis — only one or two small trials exist per condition, so the encouraging early results need confirmation in larger studies before they can guide treatment decisions.
• Oral lichen planus, despite having the second-highest number of trials (six), did not show a statistically significant benefit from curcumin on its main combined lesion-severity measure, illustrating that more trials do not always mean a stronger treatment effect.

Common questions